Acorda Therapeutics, Inc. (ACOR) Misses Q3 EPS Views; Reaffirms Outlook
Tweet
Share
E-mailGet Alerts ACOR Hot Sheet
Join SI Premium – FREE
Acorda Therapeutics, Inc. (NASDAQ: ACOR) reported Q3 EPS of $0.40, $0.33 worse than the analyst estimate of $0.73. Revenue for the quarter came in at $93.03 million versus the consensus estimate of $90.78 million.
Acorda reiterates its 2011 net sales guidance.
Acorda reiterates its 2011 net sales guidance.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
- Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
